This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanchez-Cespedes, M. Articles by Ahrendt, S. A. Search for Related Content PubMed PubMed Citation Articles by Sanchez-Cespedes, M. Articles by Ahrendt, S. A.

Increased Loss of Chromosome 9p21 but not p16 Inactivation in Primary Non-Small Cell Lung Cancer from Smokers¹

Department of Otolaryngology [M. S-C., D. S.], Oncology Center [M. E., J. G. H.], and Department of Pathology [W. H. W.], The Johns Hopkins University, Baltimore, Maryland 21287, and Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin 53226 [P. A. D., K. M. D., E. A. A., M. J. D., S. A. A.]

Epidemiological studies have demonstrated a causal association between tobacco use and carcinoma of the lung, and some genetic targets of the carcinogens in cigarette smoke have been defined recently. We further examined the effect of cigarette smoking on the frequency of allelic losses on chromosome 9p21 and the incidence of p16 inactivation. Chromosomal loss at 9p21–24 was determined by microsatellite analysis using 14 markers in 47 patients with non-small cell lung cancer. In addition, p16 gene inactivation was determined by DNA sequence analysis, methylation-specific PCR, and immunohistochemistry. Tumors from a group of nonsmokers (n = 14) were compared with tumors from a group of smokers (n = 33) matched for cell type, tumor stage, and gender. Allelic loss encompassing the p16 locus was present significantly (P = 0.01) more often in smokers (23 of 33 smokers, 70%) than in nonsmokers (4 of 14 nonsmokers, 28%). No significant differences in the frequency of p16 inactivation were observed between smokers and nonsmokers (45% versus 36%). However, homozygous deletion of the p16 gene locus and point mutation of p16 gene were only observed in tumors from smokers, whereas the p16 gene was inactivated in tumors from nonsmokers only through promoter hypermethylation. Thus, inactivation of the p16 gene is a common event in all non-small cell lung cancer, but the mechanism of gene alteration differs between smokers and nonsmokers. The significant link between tobacco and loss of the p16 locus identifies additional genetic targets of smoking in the pathogenesis of lung cancer.

This article has been cited by other articles:

				R. Iwakawa, T. Kohno, Y. Anami, M. Noguchi, K. Suzuki, Y. Matsuno, K. Mishima, R. Nishikawa, F. Tashiro, and J. Yokota Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma Clin. Cancer Res., June 15, 2008; 14(12): 3746 - 3753. [Abstract] [Full Text] [PDF]

				K. Ueda, M. Jinbo, T.-S. Li, T. Yagi, K. Suga, and K. Hamano Computed Tomography-Diagnosed Emphysema, Not Airway Obstruction, Is Associated with the Prognostic Outcome of Early-Stage Lung Cancer. Clin. Cancer Res., November 15, 2006; 12(22): 6730 - 6736. [Abstract] [Full Text] [PDF]

				R A Oldenburg, W H de Vos tot Nederveen Cappel, M van Puijenbroek, A van den Ouweland, E Bakker, G Griffioen, P Devilee, C J Cornelisse, H Meijers-Heijboer, H F A Vasen, et al. Extending the p16-Leiden tumour spectrum by respiratory tract tumours J. Med. Genet., March 1, 2004; 41(3): e31 - 31. [Full Text] [PDF]

				M. Santos Romeo, I. A. Sokolova, L. E. Morrison, C. Zeng, A. E. Baron, F. R. Hirsch, Y. E. Miller, W. A. Franklin, and M. Varella-Garcia Chromosomal Abnormalities in Non-Small Cell Lung Carcinomas and in Bronchial Epithelia of High-Risk Smokers Detected by Multi-Target Interphase Fluorescence in Situ Hybridization J. Mol. Diagn., May 1, 2003; 5(2): 103 - 112. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				L. A. Kresty, S. R. Mallery, T. J. Knobloch, H. Song, M. Lloyd, B. C. Casto, and C. M. Weghorst Alterations of p16INK4a and p14ARF in Patients with Severe Oral Epithelial Dysplasia Cancer Res., September 15, 2002; 62(18): 5295 - 5300. [Abstract] [Full Text] [PDF]

				M. Hiroyasu, M. Ozeki, H. Kohda, M. Echizenya, T. Tanaka, H. Hiai, and S. Toyokuni Specific Allelic Loss of p16 INK4A Tumor Suppressor Gene after Weeks of Iron-Mediated Oxidative Damage during Rat Renal Carcinogenesis Am. J. Pathol., February 1, 2002; 160(2): 419 - 424. [Abstract] [Full Text] [PDF]